Sep 24, 2025 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – September 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, announced today the peer-reviewed publication of independent preclinical data demonstrating the superiority of its lead antiviral candidate, Ruvidar®, in the destruction of Herpes Simplex Virus Type 1 (“HSV-1“). The latest preclinical data was published in MDPI – Viruses titled, “Ruvidar®-An Effective Anti-Herpes Simplex Virus Agent” and is available for viewing at: Website: https://www.mdpi.com/1999-4915/17/9/1280PDF Version: https://www.mdpi.com/1999-4915/17/9/1280/pdf This peer-reviewed publication provides strong support that Ruvidar® is more effective in the treatment of HSV-1 than either Acyclovir® or Metformin®, even without light-activation. Acyclovir® and its derivatives are currently known as the gold standard treatment for HSV-1.1 According to this latest research, Acyclovir® and Metformin® had little, if any, effect on the virus, once infection … Read More

Ruvidar™ (1%) showed superior efficacy in healing HSV-1 lesions in mice versus FDA-approved Acyclovir (5%) and Abreva (10%). Ruvidar™ requires fewer applications and works via novel electrostatic repulsion mechanisms blocking viral binding.

A BCG-unresponsive bladder cancer patient achieved a 7-year complete response after one Ruvidar™ treatment activated by light. Theralase® plans regulatory submissions and expanded clinical trials in 2025–2026 for hard-to-treat cancers and infections.

Ruvidar™ showed superior efficacy over Acyclovir and Abreva in treating HSV-1 in a mouse model. Theralase® plans topical formulation, toxicology, and Phase I/II trials pending funding in 2025.

Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it’s lead drug formulation, Ruvidar TM , has been demonstrated preclinically to be more effective in the destruction of the Herpes Simplex Virus 1 (“HSV-1“) than the currently approved standard of care drug, Acyclovir. Acyclovir is an antiviral drug used to slow the growth and spread of the HSV-1 virus in the body. Acyclovir will not cure herpes, but it can lessen the symptoms of the infection. It is used to treat infections caused by herpes viruses, such … Read More

June 10, 2024 – Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation.

Toronto, Ontario – September 29, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds (“PDCs”), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses, when light or radiation activated. Supported by current Good Manufacturing Practice (“cGMP”) analysis conducted by an independent manufacturing and testing laboratory, Theralase® announced that it has successfully demonstrated an 8 year, real-time, shelf life of its lead PDC, RuvidarTM. Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, “Theralase®’s ability to demonstrate such an extended shelf life of its lead PDC, RuvidarTM is extremely encouraging, as it supports our ongoing clinical development plans. This independent analysis confirms the ability of RuvidarTM to be an extremely stable small molecule that has the … Read More

TMX Newsfile | Feb 2, 2026 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – February 2, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully completed its targeted milestone of enrolling and treating 90 patients in a multi-center Phase II clinical study for bladder cancer. The Phase II clinical study has a primary endpoint of efficacy, a secondary endpoint of duration of response and a tertiary endpoint of safety, in evaluating light-activated Ruvidar® in the treatment of patients diagnosed with Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“), who have failed standard-of-care therapy and are facing radical cystectomy (bladder removal) (“Study II“). The … Read More

Toronto, Ontario, January 12, 2026 – Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have entered into a collaborative clinical development agreement (“Agreement”), on January 9, 2026. The Agreement builds on Theralase®’s existing clinical program (NCT03945162) with a new cohort investigating Theralase®’s investigational light-activated small molecule Ruvidar® (TLD-1433) in combination with Ferring’s intravesical non-replicating gene therapy ADSTILADRIN(nadofaragene firadenovec-vncg) for adult patients diagnosed with high-risk Bacillus Calmette-Guérin (“BCG”)-unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) with or without papillary tumors (±Ta/T1). Under the terms of the Agreement, Theralase® will remain the sponsor of the study, with both parties providing clinical overview of the new cohort through a joint development committee. The new cohort will be enrolled and treated in the United States and then subject to written agreement may expand into Canada or other countries. “The introduction of ADSTILADRIN, as the first intravesical gene therapy, … Read More

Newsfile | Nov 24, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation (“RCC“) as the sole agent and bookrunner on a commercially reasonable “best efforts” agency basis, for a brokered private placement offering (“Offering“) of units of the Company (“Units“) at a price of C$ 0.17 per Unit to raise a minimum of C$ 4,500,000 and up to a maximum of C$5,500,000 in aggregate gross proceeds. Each Unit will consist of one common share of the Company (“Common Share“) and one Common Share purchase warrant (“Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common Share (“Warrant Share“) at an … Read More